title: APOC3, coronary disease, and complexities of Mendelian randomization.
abstract: Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: jonathan.cohen@utsouthwestern.edu.
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Cohen
authors.affiliation: Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
authors.forename: Stefan
authors.initials: S
authors.lastname: Stender
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: helen.hobbs@utsouthwestern.edu.
authors.forename: Helen H
authors.initials: HH
authors.lastname: Hobbs
mesh_terms: D053305:Apolipoprotein C-III / Q000235:genetics*; D003327:Coronary Disease / Q000235:genetics*; D005260:Female; D006801:Humans; D007511:Ischemia / Q000235:genetics*; D008297:Male; D009154:Mutation; D017202:Myocardial Ischemia / Q000235:genetics*; D014280:Triglycerides / Q000097:blood*
chemical_list: D053305:Apolipoprotein C-III; D014280:Triglycerides